The Science of Aging: Therapeutic Approaches to Extend Lifespan and Healthspan

The growing field of antiaging pharmacology represents a significant shift in our understanding of aging, characterized by progressive physiological decline and increased susceptibility to diseases. The World Health Organization estimates that by 2050, the number of individuals aged 60 years and older will reach 2 billion, emphasizing the need for interventions that not only extend lifespan but also enhance healthspan(definition) – the duration of life spent free from chronic disease. Key mechanisms of aging include cellular senescence(definition), inflammation, mitochondrial dysfunction(definition), and telomere(definition) shortening, which collectively contribute to age-related diseases such as cardiovascular disorders and neurodegeneration. Promising candidates for antiaging therapies include mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition), metformin, and senolytics(definition). Rapamycin, a mechanistic target of rapamycin inhibitor, has demonstrated lifespan-extending properties in preclinical studies by inducing autophagy(definition) and maintaining cellular integrity. Metformin has been recognized for its potential to enhance insulin sensitivity and metabolic health, leading to the ongoing Targeting Aging with Metformin trial, which investigates its effects on age-related conditions. Senolytics are designed to eliminate senescent cells linked to tissue dysfunction and may improve age-related phenotypes. Current clinical trials are vital in assessing the safety and efficacy of these potential therapies, focusing on the distinction between lifespan and healthspan. Investigating nicotinamide adenine dinucleotide (NAD+) precursors such as nicotinamide riboside and nicotinamide mononucleotide also presents new avenues for reversing cellular aging mechanisms. Incorporating biomarker assessments will help monitor biological age and support personalized treatment approaches. Despite these advancements, ethical considerations surrounding accessibility, resource allocation, and the implications of treating aging as a modifiable condition must be addressed. The future of antiaging therapeutics lies in interdisciplinary collaboration, precision medicine, and the continual exploration of aging biology – signaling a promising path toward improving health outcomes for an aging population.